Progressive Pulmonary FibrosisNCT07269262
SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
A study testing SUPPORT-T Educational Intervention in people with Progressive Pulmonary Fibrosis and Interstitial Lung Disease, run by Medical University of South Carolina at 1 site in United States.
Trial summary
This pilot randomized controlled trial evaluates the feasibility, acceptability, and accessibility of SUPPORT-T, a digitally delivered palliative care intervention for patients with Progressive Pulmonary Fibrosis (PPF) and their caregivers. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Progressive Pulmonary Fibrosis, Interstitial Lung Disease
- What is being tested?
- SUPPORT-T Educational Intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 170 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Jan 2026to 1 Oct 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults ≥18 years
- Confirmed diagnosis of PPF
- English or Spanish speaking
- Caregiver Inclusion Criteria:
- adult, ≥ 18 years old
- Designated and identified by patient as providing most of the emotional, financial, and/or physical support (i.e., the individual most involved in care, does not have to live with patient)
- Able to speak and understand English.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Medical University of South Carolina
Charleston, South Carolina, 29425
Mary Chris Pittman, BA, 8432594689, pittmama@musc.edu
Kathleen Lindell, PhD, RN, ATSF, FAAN, (843) 792-9763, lindellk@musc.edu
About this study
Official title: Feasibility and Acceptability of a Mobile Application "SUPPORT-T" to Increase Equitable Access to Palliative Care in Patients With Progressive Pulmonary Fibrosis (PPF) and Their Caregivers
This pilot randomized controlled trial evaluates the feasibility, acceptability, and accessibility of SUPPORT-T, a digitally delivered palliative care intervention for patients with Progressive Pulmonary Fibrosis (PPF) and their caregivers. The intervention includes a 9-week digital application guided by a nurse interventionist and quarterly virtual support groups over one year. Participants will be recruited from rural South Carolina and urban New York City. The study compares SUPPORT-T to Enhanced Usual Care and aims to inform a future multi-site trial.
- Being tested
- SUPPORT-T Educational Intervention
- Keywords
- Education, Interstitial Lung Disease (ILD)
- Medical subject headings
- Lung Diseases, Interstitial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SUPPORT-T Educational InterventionOther
SUPPORT-T will be delivered biweekly at TeleHealth Visits 1-4 via a secure interface via MUSC telehealth platform. The nurse interventionist will receive results from the REDCap survey after each TH visit and contact the patient biweekly after each TH visit using the MUSC Telehealth and/or Health platform. The nurse interventionist will be available for any questions and communicate with the participants via bi-directional texts (SC will maintain a log of those texts)
| Study group | Role | What they receive |
|---|---|---|
| SUPPORT-T Intervention Arm | Experimental | Participants in the intervention arm will have a telehealth preparatory visit scheduled 1 week later (Week 2) with the Study Coordinator and will be provided with the study number to call with questions.
SUPPORT-T will be delivered biweekly at TeleHealth Visits 1-4 via a secure interface via MUSC telehealth platform. The nurse interventionist will receive results from the REDCap survey after each TH visit and contact the patient biweekly after each TH visit using the MUSC Telehealth and/or Health platform. The nurse interventionist will be available for any questions and communicate with the participants via bi-directional texts (SC will maintain a log of those texts).
• All participants will complete questionnaires at Week 1, Week 9, Month 6, and Month 12 Receives: Other: SUPPORT-T Educational Intervention |
| Enhanced Usual Care Control Group | No intervention | * Participants in the enhanced usual care arm will receive printed education materials from the Pulmonary Fibrosis Foundation (PFF) and the nurse interventionist's contact information. * All participants will complete questionnaires at Week 1, Week 9, Month 6, and Month 12 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of Disease Preparedness
Feasibility outcomes include number of participants recruited weekly, number of participants who declined, and number of participants who did not meet eligibility requirements, data collection procedures, and participant responses. Feasibility data will inform future studies on approaches for recruitment and retention, study procedures, and timing and participant capacity to complete surveys/interviews.
Measured: 10 months
Disease Preparedness Feasibility
Feasibility outcomes include number of participants recruited weekly, number of participants who declined, and number of participants who did not meet eligibility requirements, data collection procedures, and participant responses. Feasibility data will inform future studies on approaches for recruitment and retention, study procedures, and timing and participant capacity to complete surveys/interviews.
Measured: 10 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2025
- Study start13 Jan 2026
- Primary completion31 Aug 2027 (estimated)
- Study completion1 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Progressive Pulmonary FibrosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 170 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of South Carolina
- Sponsor type
- University, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- Responsible party
- Principal investigator, Kathleen Lindell, Medical University of South Carolina
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07269262
- Sponsor's protocol ID
- Pro00146761
- Status last verified
- Sep 2026
- First submitted
- 25 Nov 2025
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes